Member Info for jimbo123elf

If people think £2.2m to £2.7k could go back to £2.2m one day, then I don't think they really understand markets or placings.

Jefferies downgrade to Hold, cut PT to 190p. Third downgrade in a week.

Two broker downgrades this morning

Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal
https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/

I missed it. What were the key takeaways?

Sorry, a little under 1% of the company,

A large trade went through at 3:24pm. More than 2.1% of the company.

New announcement. Today we have signed a major new agreement with the UKAEA for the construction of a new facility for our ‘Gain’ demonstrator at Culham.

hxxps://firstlightfusion.com/media/first-light-fusion-signs-agreement-with-uk-atomic-energy-authoritygratulates-nif-on-its-maiden-gain-result-2

Damn. I better get the summer holiday booked before prices go up too much!

Not alone sir!

Very poor management this year. Nobody knew winter was coming?

All bluster and little delivery

Well that was a nice surprise!

Arecor collaborates with top global pharma company. The industry are clearly recognising the value Arecor bring to the table.

New video:
ttps://www.youtube.com/watch?v=h9llHOivZ7Q&t=323s

EU health agency urges member states to plan for monkeypox jabs.
https://www.ft.com/content/11df80f5-32d5-4bb3-8215-420574f276c4

From WHO: Polymerase chain reaction (PCR) is the preferred laboratory test given its accuracy and sensitivity. For this, optimal diagnostic samples for monkeypox are from skin lesions – the roof or fluid from vesicles and pustules, and dry crusts. Where feasible, biopsy is an option. Lesion samples must be stored in a dry, sterile tube (no viral transport media) and kept cold. PCR blood tests are usually inconclusive because of the short duration of viremia relative to the timing of specimen collection after symptoms begin and should not be routinely collected from patients.

If you think healthcare workers are going to go around extracting lesions from people en masse and running them through PCR then I think you are playing the theme slightly sub-optimally here.

PCR tests for monkeypox already exist. This isn't like COVID where Novacyt had first mover advantage in producing the first CE-marked COVID-19 test. I would suggest other stocks with monkeypox approved products already on the market would be a better play.

INBRX-101 (a candidate developed by Arecor) Phase 1 topline results showed a favourable safety profile and demonstrated potential to achieve normal functional Alpha-1 antitrypsin levels with monthly dosing in patients with Alpha-1 antitrypsin deficiency (AATD).

Lots of noise here, but given that its only Exec Director has strong links to Greenland (who changed their government last year to an Inuit one in order to block a mining company that Rod McIllree (ED) was a founding MD of) and given the 2-for-1 investor warrants (despite a slightly misleading first RNS saying no warrants), upon closer inspection this one is definitely a pass for me. As always DYOR.